Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adaptimmune Therapeutics plc - American Depositary Shares (NQ: ADAP )

0.2602 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.2602
Bid (Size) 0.2352 (1)
Ask (Size) 0.2875 (2)
Prev. Close 0.2602
Today's Range 0.2602 - 0.2602
52wk Range 0.1951 - 1.480
Shares Outstanding 1,535,653,620
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga

Performance

YTD
-58.27%
-58.27%
1 Month
-6.00%
-6.00%
3 Month
-54.72%
-54.72%
6 Month
-66.85%
-66.85%
1 Year
-77.18%
-77.18%

More News

Read More
Tuesday's after hours session: top gainers and losers
Via Chartmill
What Analysts Are Saying About Adaptimmune Therapeutics Stock
Via Benzinga
Demystifying Adaptimmune Therapeutics: Insights From 4 Analyst Reviews
Via Benzinga
Earnings Scheduled For November 13, 2024
Via Benzinga
An Overview of Adaptimmune Therapeutics's Earnings
Via Benzinga
Get insights into the top gainers and losers of Thursday's after-hours session.
Via Chartmill
Here are the top movers in Thursday's session.
Via Chartmill
Top movers in Thursday's session
Via Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Which stocks are gapping on Thursday?
Via Chartmill
Dow Gains Over 100 Points; Accenture Shares Plunge After Q2 Results
Via Benzinga
Topics Stocks
Exposures US Equities
Adaptimmune Provides Q4 and Full Year 2024 Business Update
Via Newsfile
Earnings Scheduled For March 20, 2025
Via Benzinga
Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025
Via Newsfile
Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025
Via Newsfile
Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
Via Newsfile
Exposures Product Safety
Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK
Via Newsfile
Topics Initial Public Offering
Exposures Securities Market
First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)
Via Newsfile
Adaptimmune Reports Q3 2024 Financial and Business Updates
Via Newsfile
Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial
Via Newsfile
Adaptimmune to Participate in Scientific and Medical Conferences this November and December
Via Newsfile
Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024
Via Newsfile
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.